CY1106950T1 - Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων - Google Patents

Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων

Info

Publication number
CY1106950T1
CY1106950T1 CY20071101359T CY071101359T CY1106950T1 CY 1106950 T1 CY1106950 T1 CY 1106950T1 CY 20071101359 T CY20071101359 T CY 20071101359T CY 071101359 T CY071101359 T CY 071101359T CY 1106950 T1 CY1106950 T1 CY 1106950T1
Authority
CY
Cyprus
Prior art keywords
sodium
tenatoprazol
monohydrate
pump suspension
suspension application
Prior art date
Application number
CY20071101359T
Other languages
English (en)
Inventor
Avraham Cohen
François Schutze
Suzy Charbit
Frédéric MARTINET
Hervé FICHEUX
Michel Homerin
Original Assignee
Sidem Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidem Pharma Sa filed Critical Sidem Pharma Sa
Publication of CY1106950T1 publication Critical patent/CY1106950T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η εφεύρεση αφορά το μονοένυδρο άλας νατρίου της τενατοπραζόλης, παριστώμενο από τον τύπο: Εφαρμογή στη θεραπευτική για την αγωγή των πεπτικών παθήσεων.
CY20071101359T 2004-06-17 2007-10-22 Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων CY1106950T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406617A FR2871800B1 (fr) 2004-06-17 2004-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en therapeutique
EP05778749A EP1664044B1 (fr) 2004-06-17 2005-06-17 Sel de sodium monohydrate du s-tenatoprazole et application en tant qu'inhibiteur de la pompe a protons

Publications (1)

Publication Number Publication Date
CY1106950T1 true CY1106950T1 (el) 2012-09-26

Family

ID=34948439

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101359T CY1106950T1 (el) 2004-06-17 2007-10-22 Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων

Country Status (23)

Country Link
US (1) US7402593B2 (el)
EP (1) EP1664044B1 (el)
JP (1) JP5393028B2 (el)
KR (1) KR101174932B1 (el)
CN (1) CN101001858B (el)
AT (1) ATE369366T1 (el)
AU (1) AU2005261580C1 (el)
BR (1) BRPI0512151A (el)
CA (1) CA2568993C (el)
CY (1) CY1106950T1 (el)
DE (1) DE602005001918T2 (el)
DK (1) DK1664044T3 (el)
ES (1) ES2290921T3 (el)
FR (1) FR2871800B1 (el)
HK (1) HK1106246A1 (el)
IL (1) IL179813A (el)
MX (1) MXPA06014849A (el)
NO (1) NO20070250L (el)
NZ (1) NZ551866A (el)
PL (1) PL1664044T3 (el)
PT (1) PT1664044E (el)
RU (1) RU2376304C2 (el)
WO (1) WO2006005853A1 (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
FR2909380B1 (fr) * 2006-12-04 2009-02-20 Sidem Pharma Sa Sa Conglomerats de sels de potassium de tenatoprazole
CN102276602A (zh) * 2011-06-30 2011-12-14 福建省福抗药业股份有限公司 一种泰妥拉唑盐的精制方法
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
JPH0643426B2 (ja) * 1986-07-25 1994-06-08 東京田辺製薬株式会社 イミダゾ〔４，５−ｂ〕ピリジン誘導体、その製造法及びそれを含有する抗潰瘍剤
JPH07157430A (ja) * 1993-10-12 1995-06-20 Tokyo Tanabe Co Ltd 安定化された医薬組成物
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
JPH08239381A (ja) * 1995-03-02 1996-09-17 Toa Eiyoo Kk 安定なベンズイミダゾール誘導体金属塩の溶媒和物及びその製造法並びにそれを含有する抗潰瘍剤
SE510643C2 (sv) * 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
CA2417311C (en) * 2000-08-04 2012-07-10 Takeda Chemical Industries, Ltd. Crystalline alkali metal salts of lansoprazole and their production and use
WO2002062786A1 (en) * 2001-02-02 2002-08-15 Teva Pharmaceutical Industries Ltd. Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles
CN1453278A (zh) * 2002-04-23 2003-11-05 中国人民解放军军事医学科学院放射医学研究所 一种拉唑类化合物及其制备方法与应用
FR2845917B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire
FR2845916B1 (fr) * 2002-10-21 2006-07-07 Negma Gild Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine
FR2845915B1 (fr) * 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
BRPI0310118B1 (pt) * 2002-12-06 2015-10-20 Altana Pharma Ag processo para a preparação de inibidores de bomba de próton (ppi) opticamente puro possuindo uma estrutura de sulfinila
FR2848555B1 (fr) * 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
US7507746B2 (en) * 2003-02-24 2009-03-24 Mitsubishi Pharma Corporation Enantiomer of tenatoprazole and the use thereof in therapy
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2006523201A (ja) * 2003-03-28 2006-10-12 シデム ファーマ スルホキシド誘導体をエナンチオ選択的に調製する方法

Also Published As

Publication number Publication date
CN101001858B (zh) 2012-03-14
IL179813A0 (en) 2007-05-15
AU2005261580C1 (en) 2011-06-16
JP2008502665A (ja) 2008-01-31
BRPI0512151A (pt) 2008-02-12
DE602005001918D1 (de) 2007-09-20
MXPA06014849A (es) 2007-03-23
PL1664044T3 (pl) 2007-12-31
DK1664044T3 (da) 2007-12-27
WO2006005853A1 (fr) 2006-01-19
FR2871800A1 (fr) 2005-12-23
AU2005261580B2 (en) 2011-02-03
NO20070250L (no) 2007-03-14
FR2871800B1 (fr) 2006-08-25
JP5393028B2 (ja) 2014-01-22
KR20070045194A (ko) 2007-05-02
US7402593B2 (en) 2008-07-22
ES2290921T3 (es) 2008-02-16
CN101001858A (zh) 2007-07-18
IL179813A (en) 2011-01-31
NZ551866A (en) 2010-07-30
ATE369366T1 (de) 2007-08-15
PT1664044E (pt) 2007-11-19
DE602005001918T2 (de) 2008-04-24
EP1664044A1 (fr) 2006-06-07
US20070179176A1 (en) 2007-08-02
RU2007101521A (ru) 2008-07-27
CA2568993A1 (fr) 2006-01-19
RU2376304C2 (ru) 2009-12-20
EP1664044B1 (fr) 2007-08-08
CA2568993C (fr) 2013-12-17
AU2005261580A1 (en) 2006-01-19
KR101174932B1 (ko) 2012-08-20
HK1106246A1 (en) 2008-03-07

Similar Documents

Publication Publication Date Title
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
HRP20050318A2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflamatory, ischaemic and remodelling processes
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
ATE408601T1 (de) Fredericamycin-derivate
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
MX2007003013A (es) Amidas biciclicas como inhibidores de cinasa.
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
EA200802213A1 (ru) Способы лечения заболеваний крови
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE411022T1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
EA200971107A1 (ru) Катехоламиновые производные, полезные для лечения болезни паркинсона
ATE448232T1 (de) Substituierte heterozyklen
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
UA90698C2 (en) Triazole substituted aminobenzophenone compounds
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
ATE396970T1 (de) 2-(1h-indolylsulfanyl)-benzylaminderivate als ssri
ATE543492T1 (de) Behandlung von lungenkrebs
EA201170344A1 (ru) Азаиндольные ингибиторы iap
CY1106950T1 (el) Μονοενυδρο αλας νατριου της s-tενατοπραζολης και εφαρμογη υπο τυπον αναστολεα αντλιας πρωτονιων
EA200501310A1 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения боли
EA200701813A1 (ru) Новые амидозамещенные 6-фенилфенантридины